Physician profile
Li Kong
NPI 1942680897
$2,219.86
in general payments reported to CMS, 2019-2025
15 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.30 · 2021: $192 · 2022: $295 · 2023: $429 · 2024: $426 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.61 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $437.93 | 2024-2025 | Voquezna |
| Pfizer INC. | $268.81 | 2023-2024 | |
| Lilly USA, LLC | $253.52 | 2023-2025 | Mounjaro, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $212.83 | 2022 | |
| Amgen INC. | $125.00 | 2025 | Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $124.33 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $107.28 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $46.49 | 2024-2025 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $31.96 | 2021 | |
| Ibsa Pharma INC. | $19.70 | 2021 | |
| Esperion Therapeutics, INC. | $19.53 | 2024 | Nexletol |
| Shionogi INC | $18.77 | 2024 | Fetroja |
| Abbott Laboratories | $16.80 | 2025 | Esprit |
| Getinge USA Sales, LLC | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.